Santafe News Online

DelveInsight’s “IgA Nephropathy Pipeline Insight 2025” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the IgA Nephropathy pipeline landscape. It covers the IgA Nephropathy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the IgA Nephropathy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the IgA Nephropathy Pipeline? Click here to explore the therapies and trials making headlines @ IgA Nephropathy Pipeline Outlook Report

Key Takeaways from the IgA Nephropathy Pipeline Report

• On 14 October 2025, Alpine Immune Sciences Inc. announced a clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis – LN), or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) to determine if povetacicept is safe and potentially beneficial in treating these diseases.
• On 08 October 2025, Novartis Pharmaceuticals conducted a study is designed as a multicenter, randomized, double-blind, placebo-controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d. compared to placebo on top of maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

• DelveInsight’s IgA Nephropathy Pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for IgA Nephropathy treatment.
• The leading IgA Nephropathy Companies such as Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Takeda, Selecta Biosciences, Shanghai Alebund Pharmaceuticals and others.
• Promising IgA Nephropathy Therapies such as LNP023, Blisibimod, HR19042 Capsules, Telitacicept, Intravenous Rituximab, Nefecon, BION-1301, Atrasentan, and others.

Want to know which companies are leading innovation in IgA Nephropathy? Dive into the full pipeline insights @ IgA Nephropathy Clinical Trials Assessment

The IgA Nephropathy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The IgA Nephropathy Pipeline Report also highlights the unmet needs with respect to the IgA Nephropathy.

IgA Nephropathy Overview

IgA nephropathy (IgAN), or Berger’s disease, is the most common primary glomerular disease that can progress to end stage renal failure (ESRD). Because of the critical interaction between an intrinsic antigen (galactose-deficient IgA1) and circulating anti-glycan antibodies, IgA nephropathy can be considered an autoimmune disease. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. This condition most often occurs in Caucasian and Asian males. It usually appears when people are in their teens to late 30s but can occur at any age. Many cases resolve over time. However, in a subset of patients, the disease may not resolve and thus can lead to end-stage renal disease (ESRD) after 20-25 years. Rarely the condition can progress much more rapidly leading to renal failure within a few years, if not treated.

IgA Nephropathy Emerging Drugs Profile

• Atrasentan: Chinook Therapeutics

Atrasentan is a potent and selective inhibitor of the endothelin A receptor (ETA) that has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function. Chinook selected IgAN as the lead indication for atrasentan due to the role of ETA activation in driving proteinuria, mesangial cell activation, kidney inflammation and fibrosis, the hallmarks of IgAN disease progression. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of IgA Nephropathy.

• SHR-2010: Guangdong Hengrui Pharmaceutical Co., Ltd.

SHR-2010 is a drug being studied for the treatment of Primary IgA Nephropathy. It is an injection developed by Guangdong Hengrui Pharmaceutical Co., Ltd., currently in Phase II of research. The drug is aimed at inhibiting MASP2protein. Clinical trials are ongoing to evaluate the efficacy, safety, and pharmacokinetics of SHR-2010 in patients with Primary IgA Nephropathy.

• TAK-079: Takeda

TAK-079, also known as mezagitamab, targets CD38-expressing cells, including plasmablasts, plasma cells, and natural killer cells, leading to their depletion. The rationale for using TAK-079 in IgA nephropathy is that by reducing plasma cells responsible for producing the abnormal IgA1 protein, it may help prevent the formation of pathogenic immune complexes and subsequent kidney injury. In a Phase 1b clinical trial, TAK-079 is being evaluated for safety, tolerability, pharmacokinetics, and efficacy in patients with primary IgA nephropathy who are receiving stable background therapy.

If you’re tracking ongoing IgA Nephropathy Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ IgA Nephropathy Treatment Drugs

The IgA Nephropathy Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of IgA Nephropathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for IgA Nephropathy Treatment.
• IgA Nephropathy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• IgA Nephropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the IgA Nephropathy market.

IgA Nephropathy Companies

Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Takeda, Selecta Biosciences, Shanghai Alebund Pharmaceuticals and others.

IgA Nephropathy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

IgA Nephropathy Products have been categorized under various Molecule types such as,

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the IgA Nephropathy Pipeline Report covers it all – check it out now @ IgA Nephropathy Market Drivers and Barriers, and Future Perspectives

Scope of the IgA Nephropathy Pipeline Report

• Coverage- Global

• IgA Nephropathy Companies- Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd., Takeda, Visterra, Novartis Pharmaceuticals, Wuhan Createrna Science and Technology, Jiangsu HengRui Medicine Co., Ltd., Takeda, Selecta Biosciences, Shanghai Alebund Pharmaceuticals and others.
• IgA Nephropathy Therapies- LNP023, Blisibimod, HR19042 Capsules, Telitacicept, Intravenous Rituximab, Nefecon, BION-1301, Atrasentan, and others.

• IgA Nephropathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• IgA Nephropathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the IgA Nephropathy Treatment landscape in this detailed analysis @ IgA Nephropathy Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. IgA Nephropathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. IgA Nephropathy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Atrasentan: Chinook Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SHR-2010: Guangdong Hengrui Pharmaceutical Co., Ltd.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. TAK-079: Takeda
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Product Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. IgA Nephropathy Key Companies
21. IgA Nephropathy Key Products
22. IgA Nephropathy- Unmet Needs
23. IgA Nephropathy- Market Drivers and Barriers
24. IgA Nephropathy- Future Perspectives and Conclusion
25. IgA Nephropathy Analyst Views
26. IgA Nephropathy Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight